Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-generation vs Third-generation EGFR TKIs for Advanced NSCLC With EGFR 19delins Mutation
NCT07458919Phase 1Not yet recruiting
- Sponsor
- 900th Hospital of Joint Logistics Support Force of PLA
- Start
- Mar 2026
- Primary completion
- Oct 2030
- Modality
- Orthosteric Ligands
01
Overview
Phase 1, randomised trial of icotinib and gefitinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by 900th Hospital of Joint Logistics Support Force of PLA. Primary endpoint: Progression-Free Survival at 60 months. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
icotinibgefitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07458919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07458919.